Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AnaptysBio, Inc. and Xenon Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.

About AnaptysBio, Inc. and Xenon Pharmaceuticals Inc.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Latest Biotechnology and AnaptysBio, Inc., Xenon Pharmaceuticals Inc. Stock News

As of July 31, 2026, AnaptysBio, Inc. had a $1.6 billion market capitalization, compared to the Biotechnology median of $252.6 million. AnaptysBio, Inc.’s stock is up 10.1% in 2026, down 1.5% in the previous five trading days and up 113.61% in the past year.

Currently, AnaptysBio, Inc. does not have a price-earnings ratio. AnaptysBio, Inc.’s trailing 12-month revenue is $232.4 million with a -11.5% net profit margin. Year-over-year quarterly sales growth most recently was -7.9%. Analysts expect adjusted earnings to reach $-0.231 per share for the current fiscal year. AnaptysBio, Inc. does not currently pay a dividend.

As of July 31, 2026, Xenon Pharmaceuticals Inc. had a $6.1 billion market cap, putting it in the 70th percentile of all stocks. Xenon Pharmaceuticals Inc.’s stock is up 39.8% in 2026, down 4.2% in the previous five trading days and up 103.71% in the past year.

Currently, Xenon Pharmaceuticals Inc. does not have a price-earnings ratio. Xenon Pharmaceuticals Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of July 31, 2026, Xenon Pharmaceuticals Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.810 per share for the current fiscal year. Xenon Pharmaceuticals Inc. does not currently pay a dividend.

How We Compare AnaptysBio, Inc. and Xenon Pharmaceuticals Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AnaptysBio, Inc. and Xenon Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AnaptysBio, Inc. and Xenon Pharmaceuticals Inc. Growth Grades

Company	Ticker	Growth
AnaptysBio, Inc.	ANAB	F
Xenon Pharmaceuticals Inc.	XENE	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

AnaptysBio, Inc. has a Growth Score of 12, which is Very Weak. Xenon Pharmaceuticals Inc. has a Growth Score of 0, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. is the better investment when it comes to sustainable growth.

AnaptysBio, Inc. and Xenon Pharmaceuticals Inc.’s Quality Grades

Company	Ticker	Quality
AnaptysBio, Inc.	ANAB	A
Xenon Pharmaceuticals Inc.	XENE	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

AnaptysBio, Inc. has a Quality Score of 83, which is Very Strong. Xenon Pharmaceuticals Inc. has a Quality Score of 30, which is Weak.

The Quality Grade Winner: AnaptysBio, Inc.

As you can clearly see from the Quality Grade breakdown above, AnaptysBio, Inc. has a better overall quality grade than Xenon Pharmaceuticals Inc.. For investors who are looking for companies with higher quality than others in the same industry, AnaptysBio, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AnaptysBio, Inc. and Xenon Pharmaceuticals Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
AnaptysBio, Inc.	ANAB	D
Xenon Pharmaceuticals Inc.	XENE	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

AnaptysBio, Inc. has a Earnings Estimate Score of 21, which is Negative. Xenon Pharmaceuticals Inc. has a Earnings Estimate Score of 32, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. is the better investment when it comes to estimate revisions.

Other AnaptysBio, Inc. and Xenon Pharmaceuticals Inc. Grades

In addition to Estimate Revisions, Growth and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AnaptysBio, Inc. and Xenon Pharmaceuticals Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. Stock?

Overall, AnaptysBio, Inc. stock has a Growth Score of 12, Estimate Revisions Score of 21 and Quality Score of 83.

Xenon Pharmaceuticals Inc. stock has a Growth Score of 0, Estimate Revisions Score of 32 and Quality Score of 30.

Comparing AnaptysBio, Inc. and Xenon Pharmaceuticals Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.